의약품 연속 제조 시장 보고서 : 치료 영역별, 제형별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global pharmaceutical continuous manufacturing market size reached USD 1.6 Billion in 2025 . Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2034 , exhibiting a growth rate (CAGR) of 9.24% during 2026-2034 . North America exhibits a clear dominance in the market due to its advanced technological infrastructure. Moreover, rising health concerns and increasing research and development (R&D) activities are propelling the market growth. Additionally, rising demand for effective medicine production systems is positively influencing the market.

The pharmaceutical continuous manufacturing market is experiencing rapid evolution, and the global industry is increasingly adopting new technologies to improve efficiency, quality, and scalability. Sustainability is becoming a critical consideration in pharmaceutical manufacturing, and continuous production systems are aligning with green initiatives. Energy consumption is decreasing, raw material usage is becoming more efficient, and waste generation is reducing. Companies are implementing environmentally friendly processes, and carbon footprints are shrinking. Continuous manufacturing is supporting the pharmaceutical industry's commitment to sustainable development. As environmental regulations are tightening, manufacturers are aligning operations with global sustainability goals. This trend is reinforcing the attractiveness of continuous processes.

PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET TRENDS:

Growing Prevalence of Chronic Disease

The global increasing incidence of chronic diseases like diabetes, cardiovascular disease, cancer, and respiratory disease is propelling the adoption of continuous manufacturing by the pharmaceutical sector. Healthcare systems are dealing with ever-increasing numbers of patients day by day, and pharma companies are reacting accordingly by increasing production capacity. Legacy batch operations are having a hard time keeping pace with unrelenting demand for life-saving pharmaceuticals, whereas continuous production is providing quicker, more economical, and more consistent solutions for manufacturing. In permitting unbroken output of medicines, this technology is guaranteeing that supply is meeting rising therapeutic demand. Firms are also emphasizing shortening shortages and enhancing availability, especially of significant medications prescribed in extended therapy. The most recent International Diabetes Federation (IDF) Diabetes Atlas (2025) indicates that 11.1%, equivalent to 1 in 9 of adults (aged 20-79) are affected by diabetes, with more than 40% being unaware of their condition. As chronic disease prevalence is rising in both developed and emerging economies, the need for cost-effective and scalable production is growing. Continuous manufacturing is meeting this need through consistent quality and quantity, such that patients are constantly receiving vital drugs without interruption.

Technological Innovations and Developments

Rapid technological advances are driving the adoption of continuous manufacturing, as pharma companies continue to infuse production processes with automation, artificial intelligence, digital twins, and predictive analytics. Sophisticated process control systems are facilitating real-time tracking, while machine learning algorithms are predicting potential drifts and maximizing efficiency. These advances are guaranteeing consistent quality of products, minimizing downtime, and reducing variability. Modular system architecture is providing flexibility, enabling buildings to fit in several drug sizes without extensive reorganization. Businesses are also making investments in digital platforms that are offering complete transparency throughout the production cycle with end-to-end traceability. Coupled with Industry 4.0 technologies, pharmaceutical production is becoming intelligent, agile, and quicker. These technologies are establishing continuous manufacturing as the pillar of future-proof pharmaceutical manufacture to help businesses stay competitive while fulfilling mounting world demand for affordable, dependable, and high-quality drugs. IMARC Group predicts that the global industry 4.0 market is expected to attain USD 570.5 Billion by 2033.

Regulatory Support and Encouragement

Regulatory bodies are increasingly encouraging continuous manufacturing through supportive guidelines, approvals, and frameworks. The U.S. Food and Drug Administration (FDA) is promoting innovation through regulatory adaptability, whereas the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) are converging towards global standards. These agencies are opening routes to swift uptake, and the companies are reciprocating by requesting approvals for continuous manufacturing techniques. By providing guidance on compliance, regulators are encouraging pharmaceutical companies to implement real-time quality monitoring, process analytical technology (PAT), and advanced control systems. This assistance is reducing uncertainty, speeding adoption, and establishing industry confidence. With increasing case studies being approved, the regulatory environment is strengthening confidence in continuous systems. This positive attitude is propelling adoption in small-molecule medications, biologics, and the personalized medicine space, making the industry globally gradually move toward extensive integration of continuous manufacturing. In 2024, the U.S. Food and Drug Administration (FDA) declared that it will be accepting applications between Jan. 2, 2024, and March 1, 2024, for the START pilot program to accelerate the development of rare disease therapeutics. Sponsor engagement in the pilot will be deemed completed once the development program achieves a major regulatory milestone, like commencing the pivotal clinical trial phase or reaching the stage before filing a marketing application (pre-Biologics License Application or pre-New Drug Application meeting stage), as agreed with the sponsor.

PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET GROWTH DRIVERS:

Cost Savings and Operational Benefits

The pharmaceutical industry is progressively embracing continuous manufacturing due to its enormous cost-benefit potential and operational benefits. Conventional batch production is demanding big spaces, heavy manpower, and long timelines, while continuous systems are decreasing energy usage, reducing raw material use, and eliminating waste. Through process simplification, companies are lowering the cost of production and realizing more output in fewer cycles. Continuous systems are also facilitating quicker scale-up, making it possible for manufacturers to transition faster from development to full-scale manufacture. These advantages are especially crucial with competition heating up and drug pricing pressures building around the world. Continuous manufacturing is also enabling smaller manufacturing footprints, which is reducing infrastructure costs. In keeping quality constant and minimizing failures during production, companies are preventing expensive delays and recalls. This efficiency of operation is becoming a primary motivator, as the sector is always looking to reconcile affordability, compliance, and patient access without sacrificing safety or quality.

Increased Demand for Biopharmaceuticals and Advanced Therapies

The pharma industry is gravitating toward continuous manufacturing increasingly as demand for biologics, biosimilars, and advanced therapies like cell and gene therapies is increasing at a fast pace. Legacy batch processes are no longer adequate to handle the multifaceted demands of such treatments, while continuous processes are facilitating greater consistency, efficiency, and scalability. Firms are adopting continuous upstream processes like perfusion bioreactors, and continuous downstream methods like chromatography, to guarantee product quality. These approaches are minimizing cycle times and facilitating quicker market introduction for critical therapies. The biopharmaceutical industry is also calling for precise control of variability, and continuous systems are answering this call by enabling real-time monitoring and sophisticated control mechanisms. With an escalating global demand for personalized and complex treatments, continuous manufacturing is taking a leading role in serving patient needs. This change is making sure that the pharmaceutical industry is reacting to one of its most significant growth drivers effectively.

Increasing Emphasis on Supply Chain Resilience

Continuous manufacturing is increasingly being embraced by pharmaceutical firms as they focus on supply chain resilience due to global upheavals. Batch production is typically based on long supply chains and centralized plants, which are susceptible to delays and shortages. In contrast, continuous manufacturing is facilitating localized, decentralized, and flexible models of production that are diminishing dependence on elaborate logistics chains. Firms are adopting smaller, modular plants near patients to provide timely access to drugs. This strategy is also lowering risks of supply disruptions in cases of emergencies and enhancing the capacity to deal with unexpected spikes in demand. Through increased supply chain flexibility, continuous manufacturing is enabling pharmaceutical firms to respond more rapidly to changes in the marketplace. The growing focus on resilience is propelling companies towards the adoption of continuous manufacturing, as companies can now see the strategic benefit of more secure, responsive, and sustainable production schemes.

GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING INDUSTRY SEGMENTATION:

Breakup by Therapeutics Type:

• Large Molecules
• Small Molecules

Small molecules dominate the pharmaceutical continuous manufacturing market

Continuous manufacturing enhances efficiency and consistency in small-molecule drugs. Vertex Pharmaceuticals introduced Suzetrigine, a small molecule drug manufactured using continuous processes, optimizing production efficiency and ensuring consistent quality for pain management.

Breakup by Formulation:

• Solid Formulation
• Liquid and Semi-solid Formulation

Solid formulation currently holds most of the pharmaceutical continuous manufacturing market demand

Solid formulations, such as capsules and tablets, excel in continuous manufacturing due to improved consistency and efficiency. For example, XenoPharma's tablet production ensures uniform quality and scalable output, which is acting as another significant growth-inducing factor.

Breakup by Application:

• Final Drug Product Manufacturing
• API Manufacturing

Final drug product manufacturing dominates the market

Final drug product manufacturing in continuous processes ensures efficient production with consistent quality and scalability, thereby reducing waste and enhancing overall process control. It also results in cost savings. This is bolstering the pharmaceutical continuous manufacturing market revenue.

Breakup by End User:

• Pharmaceutical Companies
• Contract Manufacturing Organizations
• Others

Pharmaceutical companies hold most of the pharmaceutical continuous manufacturing market outlook

Pharmaceutical companies increasingly adopt continuous manufacturing to enhance efficiency, streamline production processes, and ensure consistent product quality. This is leading to faster and more cost-effective drug development.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest pharmaceutical continuous manufacturing market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the pharmaceutical continuous manufacturing market research report, North America accounted for the largest share, driven by advanced drug delivery technologies. Moreover, regulatory bodies in the region are highly supportive of continuous manufacturing practices. The corporation with regulatory bodies encourages pharmaceutical companies to adopt continuous manufacturing solutions, thereby propelling the market growth. For instance, in May 2024, the U.S. Food and Drug Administration (FDA) introduced the START pilot program to catalyze the development of rare disease therapeutics.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market pharmaceutical continuous manufacturing companies have also been provided. Some of the key players in the market include:

• Baker Perkins
• Coperion GmbH (Hillenbrand Inc.)
• Eli Lilly and Company
• GEA Group Aktiengesellschaft
• Glatt GmbH
• Korsch AG
• Novartis AG
• Siemens
• SK biotek
• Thermo Fisher Scientific Inc.
• Viatris Inc.

()

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the global pharmaceutical continuous manufacturing market?

2. What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2026-2034?

3. What are the key factors driving the global pharmaceutical continuous manufacturing market?

4. What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market growth?

5. What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?

6. What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?

7. What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?

8. What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?

9. What are the key regions in the global pharmaceutical continuous manufacturing market?

10. Who are the key players/companies in the global pharmaceutical continuous manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Pharmaceutical Continuous Manufacturing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapeutics Type

• 6.1 Large Molecules
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Small Molecules
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Formulation

• 7.1 Solid Formulation
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Liquid and Semi-solid Formulation
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Final Drug Product Manufacturing
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 API Manufacturing
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharmaceutical Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Contract Manufacturing Organizations
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Baker Perkins
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Coperion GmbH (Hillenbrand Inc.)
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Eli Lilly and Company
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 GEA Group Aktiengesellschaft
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Glatt GmbH
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Korsch AG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Novartis AG
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Siemens
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 SK biotek
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Thermo Fisher Scientific Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Viatris Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials